Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

G1 Therapeutics, Inc. Common Stock (GTHX)

Pharmaceutical Preparations

https://www.g1therapeutics.com

G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies.

700 PARK OFFICES DRIVE, SUITE 200
RESEARCH TRIANGLE PARK, NC

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/17/2017

Market Cap

372,243,568

Shares Outstanding

51,840,000

Weighted SO

51,843,669

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

ALLO --.--%

HRTX --.--%

ANNX --.--%

SGMO --.--%

XFOR --.--%

HOOK --.--%

MREO --.--%

GRTX --.--%

ABOS --.--%

Beta

1.5350

Last Div

0.0000

Range

1.08-7.12

Chg

0.0200

Avg Vol

1917500

Mkt Cap

372243568

Exch

NASDAQ

Country

US

Phone

919 213 9835

DCF Diff

3.5977

DCF

-0.0176

Div Yield

0.0000

P/S

6.3965

EV Multiple

-10.7976

P/FV

15.1929

Div Yield %

0.0000

P/E

-8.3454

PEG

-0.3577

Payout

0.0000

Current Ratio

2.4777

Quick Ratio

2.1208

Cash Ratio

0.4036

DSO

83.4743

DIO

795.0513

Op Cycle

878.5255

DPO

306.3053

CCC

572.2202

Gross Margin

0.8944

Op Margin

-0.6509

Pretax Margin

-0.7383

Net Margin

-0.7693

Eff Tax Rate

-0.0438

ROA

-0.4536

ROE

0.2628

ROCE

-0.6191

NI/EBT

1.0421

EBT/EBIT

1.1342

EBIT/Rev

-0.6509

Debt Ratio

0.4491

D/E

1.8021

LT Debt/Cap

0.5723

Total Debt/Cap

0.6431

Int Coverage

51.2585

CF/Debt

-0.8471

Equity Multi

4.0131

Rec Turnover

4.3726

Pay Turnover

1.1916

Inv Turnover

0.4591

FA Turnover

10.4292

Asset Turnover

0.5897

OCF/Share

-0.7154

FCF/Share

-0.7154

Cash/Share

1.1585

OCF/Sales

-0.6451

FCF/OCF

1.0000

CF Coverage

-0.8471

ST Coverage

-3.2896

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

15.1929

P/B

15.1929

P/S

6.3965

P/E

-8.3454

P/FCF

-9.9157

P/OCF

-9.9524

P/CF

-9.9524

PEG

-0.3577

P/S

6.3965

EV Multiple

-10.7976

P/FV

15.1929

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 08, 06:45 G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 02, 16:51 G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Jan 02, 16:51 G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PennyStocks Dec 06, 14:48 Best Penny Stocks To Buy? 4 To Watch With Big News This Week PennyStocks Dec 06, 14:48 Best Penny Stocks To Buy? 4 To Watch With Big News This Week GlobeNewswire Inc. Dec 05, 09:26 G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy GlobeNewswire Inc. Dec 01, 16:27 G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 29, 20:37 G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium GlobeNewswire Inc. Nov 29, 20:37 G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium GlobeNewswire Inc. Nov 29, 20:37 G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium GlobeNewswire Inc. Nov 01, 06:30 G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights PennyStocks Oct 31, 14:18 Penny Stocks To Buy Today? 4 To Watch Now

Revenue Product Segmentation